Abstract
Deep brain stimulation (DBS) of the subcallosal cingulate cortex (SCC) is an experimental therapy for treatment-resistant depression (TRD). Chronic SCC DBS leads to long-term changes in the electrophysiological dynamics measured from local field potential (LFP) during wakefulness, but it is unclear how it impacts sleep-related brain activity. This is a crucial gap in knowledge, given the link between depression and sleep disturbances, and an emerging interest in the interaction between DBS, sleep, and circadian rhythms. We therefore sought to characterise changes in electrophysiological markers of sleep associated with DBS treatment for depression. We analysed key electrophysiological signatures of sleep – slow-wave activity (SWA, 0.5-4.5Hz) and sleep spindles – in LFPs recorded from the SCC of 9 patients who responded to DBS for TRD. This allowed us to compare the electrophysiological changes before and after 24 weeks of therapeutically effective SCC DBS.
SWA power was highly correlated between hemispheres, consistent with a global sleep state. Furthermore, SWA occurred earlier in the night after chronic DBS and had a more prominent peak. While we found no evidence for changes to slow wave power or stability, we found an increase in the density of sleep spindles. Our results represent a first-of-its-kind report on long-term electrophysiological markers of sleep recorded from the SCC in patients with TRD, and provides evidence of earlier NREM sleep and increased sleep spindle activity following clinically effective DBS treatment. Future work is needed to establish the causal relationship between long-term DBS and the neural mechanisms underlying sleep.
Conflict of interest statement JJvR has received honoraria from Medtronic. TD is a founder and director of Amber who own Bioinduction Ltd, has received honoraria from Medtronic, and is an advisor for Cortec Neuro and Synchron. PR-P receives consulting fees from Abbott Labs, LivaNova, and Janssen Pharmaceuticals. HM receives consulting and Intellectual Property licensing fees from Abbott Labs. SA, CR, ACW and AS have nothing to declare.
Competing Interest Statement
JJvR has received honoraria from Medtronic. TD is a founder and director of Amber who own Bioinduction Ltd, has received honoraria from Medtronic, and is an advisor for Cortec Neuro and Synchron. PR-P receives consulting fees from Abbott Labs, LivaNova, and Janssen Pharmaceuticals. HM receives consulting and Intellectual Property licensing fees from Abbott Labs. SA, CR, ACW and AS have nothing to declare.
Clinical Trial
NCT01984710
Funding Statement
This study was supported by the following grants: Hope for Depression Research Founda-tion, NIH UH3NS103550; Medical Research Council UK, MC_UU_00003/6 to AS and MC_UU_00003/3 to TD. The Activa PC + S DBS devices used in this study were donated by Medtronic.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board of Emory University gave ethical approval for this work. Institutional review board of Icahn School of Medicine at Mt Sinai gave ethical approval for this work. Institutional review board of Georgia Institute of Technology gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The anonymised raw data (LFP timeseries and associated timestamps, as well as associated clinical data) are publicly available as part of the data set released for Alagapan et al. 2023 [42] via the Data Archive for the Brain Initiative (DABI) at https://dabi.loni.usc.edu/dsi/1UH3NS103550/UXUF7822Z3JL. Pre-processed data as well as MATLAB code to reproduce figures and analyses in this paper will be made available on request from the corresponding authors.
Andrew Sharott: andrew.sharott{at}bndu.ox.ac.uk
Joram van Rheede: joram.vanrheede{at}bndu.ox.ac.uk
